TY - JOUR
T1 - Association of visceral adiposity index with new-onset type 2 diabetes and impaired fasting glucose in hypertensive Chinese adults
AU - Zhou, Chun
AU - Zhang, Zhuxian
AU - Liu, Mengyi
AU - Zhang, Yuanyuan
AU - He, Panpan
AU - Li, Qinqin
AU - Xie, Di
AU - Liang, Min
AU - Wang, Guobao
AU - Nie, Jing
AU - Liu, Chengzhang
AU - Song, Yun
AU - Liu, Lishun
AU - Wang, Binyan
AU - Wang, Xiaobin
AU - Xu, Xiping
AU - Qin, Xianhui
N1 - Funding Information:
Dr. Xiping Xu reports Grants from the National Key Research and Development Program [2016YFE0205400, 2018ZX09739010, 2018ZX09301034003], the Science and Technology Planning Project of Guangzhou, China [201707020010], the Science, Technology, and Innovation Committee of Shenzhen [JSGG20170412155639040, GJHS20170314114526143, JSGG20180703155802047], and the Economic, Trade and Information Commission of Shenzhen Municipality [20170505161556110, 20170505160926390]. Dr. Jing Nie reports grants from the National Key R&D program of China [2020YFC2005000]. Dr. Xianhui Qin reports Grants from the National Natural Science Foundation of China [81973133, 81730019]. No other disclosures were reported.
Funding Information:
The study was supported by the National Key Research and Development Program [2016YFE0205400, 2018ZX09739010, 2018ZX09301034003], the National Key Research and Development Program, China [201707020010]; National Key R&D program of China [2020YFC2005000]; the Science, Technology and Innovation Committee of Shenzhen [JSGG20170412155639040, GJHS20170314114526143, JSGG20180703155802047]; the Economic, Trade and Information Commission of Shenzhen Municipality [20170505161556110, 20170505160926390]; the National Natural Science Foundation of China [81973133, 81730019]; the Research Fund Program of Guangdong Province Key Laboratory of Renal Failure Research; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201003].
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2022/3
Y1 - 2022/3
N2 - Purpose: Visceral adiposity index (VAI) is a reliable indicator for the distribution and function of adipose tissue in the body. The relation of VAI with new-onset type 2 diabetes and new-onset impaired fasting glucose (IFG) remains uncertain. We aimed to investigate the prospective relation of VAI with new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive adults. Methods: A total of 14,838 hypertensive adults free of type 2 diabetes at baseline were included from the China Stroke Primary Prevention Trial. The primary outcome was new-onset type 2 diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up, or fasting glucose ≥ 7.0 mmol/L at the exit visit. The secondary outcome was new-onset IFG, defined as fasting glucose < 6.1 mmol/L at baseline, while fasting glucose ≥ 6.1 mmol/L and < 7.0 mmol/L at the exit visit. Results: Over a median of 4.5 years’ follow-up, 1612 (10.9%) participants developed type 2 diabetes. When VAI was categorized into quartiles, compared with participants in quartile 1–3 (< 2.80), significantly higher risk of new-onset type 2 diabetes (OR 1.30; 95% CI 1.08–1.56) and new-onset IFG (OR 1.28; 95% CI 1.08–1.52) was found in those in quartile 4 (≥ 2.80). Moreover, the positive associations were consistent in participants with or without single abnormal VAI components, including general obesity, abdominal obesity, elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C) levels; or with different numbers of abnormal VAI components (all P interactions > 0.05). Conclusion: Our study suggested a positive relation of VAI with the risk of new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive patients, independent of its components. Level of evidence: Level III, a well-designed cohort.
AB - Purpose: Visceral adiposity index (VAI) is a reliable indicator for the distribution and function of adipose tissue in the body. The relation of VAI with new-onset type 2 diabetes and new-onset impaired fasting glucose (IFG) remains uncertain. We aimed to investigate the prospective relation of VAI with new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive adults. Methods: A total of 14,838 hypertensive adults free of type 2 diabetes at baseline were included from the China Stroke Primary Prevention Trial. The primary outcome was new-onset type 2 diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up, or fasting glucose ≥ 7.0 mmol/L at the exit visit. The secondary outcome was new-onset IFG, defined as fasting glucose < 6.1 mmol/L at baseline, while fasting glucose ≥ 6.1 mmol/L and < 7.0 mmol/L at the exit visit. Results: Over a median of 4.5 years’ follow-up, 1612 (10.9%) participants developed type 2 diabetes. When VAI was categorized into quartiles, compared with participants in quartile 1–3 (< 2.80), significantly higher risk of new-onset type 2 diabetes (OR 1.30; 95% CI 1.08–1.56) and new-onset IFG (OR 1.28; 95% CI 1.08–1.52) was found in those in quartile 4 (≥ 2.80). Moreover, the positive associations were consistent in participants with or without single abnormal VAI components, including general obesity, abdominal obesity, elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C) levels; or with different numbers of abnormal VAI components (all P interactions > 0.05). Conclusion: Our study suggested a positive relation of VAI with the risk of new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive patients, independent of its components. Level of evidence: Level III, a well-designed cohort.
KW - Hypertension
KW - New-onset impair fasting glucose
KW - New-onset type 2 diabetes
KW - Visceral adiposity index
UR - http://www.scopus.com/inward/record.url?scp=85104148779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104148779&partnerID=8YFLogxK
U2 - 10.1007/s40519-021-01187-4
DO - 10.1007/s40519-021-01187-4
M3 - Article
C2 - 33844178
AN - SCOPUS:85104148779
SN - 1124-4909
VL - 27
SP - 505
EP - 514
JO - Eating and Weight Disorders
JF - Eating and Weight Disorders
IS - 2
ER -